telatinib

 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

PyridazinesPyridines
Receptor Tyrosine Kinase InhibitionTelatinib Mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
Multidrug resistance (MDR) is a phenomenon where cancer cells become simultaneously resistant to anticancer drugs with different… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
BACKGROUND Blocking both receptor and ligand of the vascular endothelial growth factor (receptor) VEGF(R) pathway might be… (More)
Is this relevant?
2011
2011
Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion.
Geldanamycin and its derivative 17AAG [17-(Allylamino)-17-demethoxygeldanamycin, telatinib] bind selectively to the Hsp90… (More)
Is this relevant?
2011
2011
Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with…
4122 Background: Angiogenesis is essential for tumor growth and plays an important role in metastasis in gastrointestinal (GI… (More)
  • figure 4
Is this relevant?
Review
2011
Review
2011
Onset of CT scan morphological changes in metastatic lesions and associated responses in gastric patients treated with telatinib.
81 Background: Response to the antiangiogenic agent, bevacizumab, by CT has been associated with a unique morphologic change in… (More)
Is this relevant?
2010
2010
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
PURPOSE We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of the… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2009
2009
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Purpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR; VEGFR-2… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients…
PURPOSE Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
PURPOSE Hypertension is a commonly reported side effect in antiangiogenic therapy. We investigated the hypothesis that telatinib… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2008
2008
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?